Veracyte, Inc.
VCYT- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001384101
In the last 90 days, Veracyte, Inc. insiders filed 0 open-market purchases and 6 sales; 370 institutions reported holding it in 13F filings for Q2 2026, worth $5.23B in total; ARK Invest is the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Veracyte, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 6 filings
- 6 insiders, $1.31M in total
- Insiders trading
- 6
- Net value
- −$1.31M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Veracyte, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Leite John | Global Chief Commercial Off | 124,329 | Sep 22, 2026 | 10 |
| Holstein Jens | Director | 27,471 | Sep 16, 2026 | 3 |
| Wygant Jonathan | VP, Chief Accounting Officer | 43,226 | Sep 4, 2026 | 8 |
| Febbo Phillip G. | Chief Scientific & Med Officer | 133,048 | Sep 4, 2026 | 7 |
| Chambers Rebecca | Chief Financial Officer | 166,025 | Sep 4, 2026 | 8 |
| McGuire Annie | EVP, General Counsel | 131,160 | Sep 4, 2026 | 11 |
| Stapley Marc | Chief Executive Officer | 432,073 | Sep 4, 2026 | 7 |
| Bhanji Muna | Director | 42,718 | Sep 3, 2026 | 2 |
| Eastham Karin | Director | 15,097 | Jun 22, 2026 | 4 |
| Jones Evan/ Fa | Director | 34,634 | Jun 15, 2026 | 3 |
| Epstein Robert S | Director | 57,718 | Jun 15, 2026 | 3 |
| Shafer David Brent | Director | 31,100 | Jun 15, 2026 | 1 |
| Barr Eliav | Director | 56,461 | Jun 15, 2026 | 1 |
| Miller Thomas F. | Director | 31,100 | Jun 15, 2026 | 1 |
| Haas Kevin Richard | Chief Dev and Tech Officer | 44,221 | Apr 14, 2026 | 1 |
| Bishop John L | Director | 33,125 | Jul 19, 2023 | 0 |
| Anderson Bonnie H | Director | 41,377 | Jun 6, 2023 | 0 |
| Kennedy Giulia C | Chief Scientific & Med Officer | 65,970 | Dec 8, 2022 | 0 |
| Gordon Kevin K | Director | 8,720 | Jun 10, 2022 | 0 |
| Nova Tina Susan | President, CLIA U.S. | 76,988 | Mar 7, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Chambers RebeccaChief Financial Officer | SSale | −3.56K | $49.73 | −$177.1K | −2.0%173.3K after | 2 lots10b5-1 |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | McGuire AnnieEVP, General Counsel | SSale | −3.18K | $49.76 | −$158.0K | −2.3%137.2K after | 2 lots10b5-1 |
| Jun 4, 2026 (view filing) | Jun 4 | Same day | Leite JohnGlobal Chief Commercial Off | SSale | −14.0K | $50.07 | −$699.7K | −9.6%132.3K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Eastham KarinDirector | SSale | −3.73K | $52.89 | −$197.2K | −19.8%15.1K after | 2 lots10b5-1 |
| Sep 3, 2026 (view filing)4:48 PM ET | Sep 1 | 2 days | Bhanji MunaDirector | SSale | −1.86K | $42.97 | −$80.1K | −4.2%42.7K after | 10b5-1 |
| Sep 4, 2026 (view filing)7:54 PM ET | Sep 4 | Same day | McGuire AnnieEVP, General Counsel | SSale | −3.25K | $43.09 | −$140.2K | −2.4%131.2K after | 2 lots10b5-1 |
| Sep 4, 2026 (view filing)7:54 PM ET | Sep 4 | Same day | Chambers RebeccaChief Financial Officer | SSale | −3.65K | $43.10 | −$157.4K | −2.2%166.0K after | 2 lots10b5-1 |
| Sep 4, 2026 (view filing)7:54 PM ET | Sep 4 | Same day | Febbo Phillip G.Chief Scientific & Med Officer | SSale | −13.1K | $43.05 | −$564.4K | −9.0%133.0K after | 2 lots10b5-1 |
| Sep 16, 2026 (view filing)4:08 PM ET | Sep 14 | 2 days | Holstein JensDirector | SSale | −5.00K | $40.95 | −$204.7K | −15.4%27.5K after | 10b5-1 |
| Sep 22, 2026 (view filing)5:16 PM ET | Sep 21 | 1 day | Leite JohnGlobal Chief Commercial Off | SSale | −4.01K | $40.00 | −$160.6K | −3.1%124.3K after | 10b5-1 |